In a quarterly filing with the SEC, investment manager Dodge & Cox disclosed a reduction in its position in GSK PLC. The report, which covers the period ending June 30, 2026, revealed the firm sold a net 10.46 million shares, decreasing its total holding by 17.84% to 48.20 million shares. It's important to note that 13F filings are submitted to regulators up to 45 days after the end of a quarter, so this disclosure reflects a portfolio snapshot from June 30 and not necessarily a recent trading decision.
Based on the reported values, the estimated value of the shares sold is approximately $548.60 million. Following the sale, GSK's weight in Dodge & Cox's portfolio decreased from 1.78% to 1.32%. This disclosure comes after a second quarter in which GSK reported a 5% increase in turnover and raised its sales and operating profit guidance for 2026.